Israel - English - Ministry of Health

cts ltd - progesterone - capsules - progesterone 100 mg - progesterone - progesterone - vaginal or oral addministration: disorders related to progesterone deficit in particular menopause ( in association with estrogen therapy).vaginal administration: progesterone substitution for ovary deprived women in situation of total progesterone deficiency. supplementation of the luteal phase during in vitro fertilization cycles. supplementation of the luteal phase during spontaneous or induced cycles, in cases of hypofertility or primary or secondary ovarain failure, particulary through dysovulation. in cases of threatning abortion or prevention of repeated abortions due to proven luteal insufficiency. for all other progesterone indications, in the case of : adverse events due to progesterone, contraindication of the oral route of administration hepatopathy.

Malta - English - Medicines Authority

seid s.a carretera de sabadell a granollers, km. 15 08185 - llica de vall barcelona, spain - estradiol - gel - estradiol 60 milligram(s) - sex hormones and modulators of the genital system

Singapore - English - HSA (Health Sciences Authority)

pfizer private limited - medroxyprogesterone acetate - injection - 50 mg/ml - medroxyprogesterone acetate 50 mg/ml

Singapore - English - HSA (Health Sciences Authority)

pfizer private limited - medroxyprogesterone acetate - injection - 150 mg/ml

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - cyproterone acetate, quantity: 50 mg - tablet, uncoated - excipient ingredients: maize starch; magnesium stearate; povidone; colloidal anhydrous silica; lactose monohydrate; pregelatinised maize starch - women: moderately severe to severe signs of androgenisation. moderately severe/severe forms of hirsutism. moderately severe/severe androgen-dependent loss of scalp hair (moderately severe/severe andogenetic alopecia). moderately severe/severe forms of acne and/or seborrhoea associated with other features of androgenisation. cyproterone acetate inhibits the influence of male sex hormones, which are also produced by the female. it is thus possible to treat diseases in women caused either by increased production of androgens or a particular sensitivity to these hormones. hirsutism and alopecia may be expected to recur over a period of time after cessation of treatment. if cyproterone is taken during pregnancy, the properties of the preparation may lead to signs of feminisation in the male foetus. therefore, in women of child bearing potential, pregnancy must be excluded at the commencement of treatment and ethinyl oestradiol taken as well to ensure contraception. this also promotes regular menstruation. . men: reduction of drive in sexual deviations. cyproterone reduces the force of the sexual urge in men with sexual deviations. whilst under treatment, the man can control himself better in a predisposing stimulatory situation, but there is no influence on any deviating direction of sexual drive. abnormal patterns of sexual behaviour require treatment when they are distressing to the patient. a prerequisite for therapy is the desire by the patient for treatment. cyproterone therapy should be supplemented by psychotherapeutic and sociotherapeutic measures in order to exploit the period of reduced drive for personal and social re-orientation. inoperable prostatic carcinoma. to suppress "flare" with initial lhrh analogue therapy. in long term palliative treatment where lhrh analogues or surgery are ineffective, not tolerated, contraindicated or where oral therapy is preferred. in the treatment of hot flushes in patients treated with lhrh analogues or who have had orchidectomy.

Canada - English - Health Canada

janssen inc - norgestimate; ethinyl estradiol - tablet - 0.25mg; 0.035mg - norgestimate 0.25mg; ethinyl estradiol 0.035mg - contraceptives